Global Coverage With Measles Vaccine Declined During COVID-19
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
MONDAY, Nov. 18, 2024 -- Global coverage with measles vaccination declined during the COVID-19 pandemic, and estimated measles cases increased 20 percent worldwide from 2022 to 2023, according to research published in the Nov. 14 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.
Anna A. Minta, M.D., from the World Health Organization in Geneva, and colleagues describe progress toward measles elimination during 2000 to 2023.
The researchers note that an estimated 60.3 million measles deaths were averted by vaccination during 2000 to 2023. However, no region successfully achieved and maintained elimination by the end of 2023, despite commitment from all six World Health Organization regions to eliminate measles. Estimated global coverage with the first dose of measles-containing vaccine (MCV1) declined to 81 percent during the COVID-19 pandemic, which was the lowest level since 2008. In 2022, MCV1 coverage improved to 83 percent, but was unchanged in 2023. Estimated measles cases increased 20 percent worldwide from 2022 to 2023, from 8,645,000 to 10,341,000; there was an increase observed in the number of countries experiencing large or disruptive outbreaks, from 36 to 57. From 2022 to 2023, there was an 8 percent decrease seen in estimated measles deaths, mainly due to an increased number of cases occurring in countries with a lower risk for death.
"Countries and global partners working together is essential to accelerate efforts to reach and sustain measles elimination," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-11-19 12:00
Read more
- Women, Men on Kidney Dialysis Face Different Heart Risks
- Camurus Provides Regulatory Update on the US NDA for CAM2029 in Acromegaly
- Higher Heart Rate May Help Spur A-fib in Black Patients
- Most Patients Can Keep Using GLP-1 Weight Loss Meds Before Surgeries
- Weight-Loss Surgery for Teens Brings Lasting Benefit
- Ozempic, Wegovy Might Help Lower Alzheimer's Risk in People With Diabetes
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions